Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 17/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.41 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22348742 | 0.93 | NR1H4 (0.46) | NR1H4HSD11B1HSD11B2 | |
| SCHEMBL22348487 | 0.90 | NR1H4 (0.61) | NR1H4 | |
| SCHEMBL22348576 | 0.89 | HDAC1 (0.47) | NR1H4HSD11B1HSD11B2 | |
| SCHEMBL22348605 | 0.88 | NR1H4 (0.46) | NR1H4HSD11B1HSD11B2 | |
| SCHEMBL22347357 | 0.85 | NR1H4 (0.60) | NR1H4 | |
| SCHEMBL22348553 | 0.84 | HSD11B1 (0.45) | NR1H4HSD11B1HSD11B2 | |
| SCHEMBL22348714 | 0.83 | HSD11B1 (0.44) | NR1H4HSD11B1HSD11B2 | |
| SCHEMBL22347940 | 0.83 | HSD11B1 (0.44) | NR1H4HSD11B1HSD11B2 | |
| SCHEMBL22348556 | 0.83 | HSD11B1 (0.46) | NR1H4HSD11B1HSD11B2 | |
| SCHEMBL22348612 | 0.82 | NR1H4 (0.44) | NR1H4HSD11B1HSD11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12319676-B2 | Substituted amide compounds useful as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-06-03 | — | — | US | disclosed |
| US-20220081430-A1 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-03-17 | — | — | US | disclosed |
| EP-3924333-A1 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2021-12-22 | — | — | EP | disclosed |
| WO-2020168149-A1 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12319676-B2 | Substituted amide compounds useful as farnesoid X receptor modulators | NR1H4, FXR1, NR1H3 | NR1H4 1/4885HSD11B1 153/4885HSD11B2 258/4885 |
| US-20220081430-A1 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | NR1H4, NR1H3, NR1H2 | NR1H4 1/4885HSD11B1 147/4885HSD11B2 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.